The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol LDL-C reductions of The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group.
This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD. Reduction in Incidence of Coronary Heart Disease. Coronavirus Resource Center. Our website uses cookies to enhance your experience. Description: Lipid-lowering for CAD in asymptomatic men with primary hypercholesterolemia. Principal Findings: With cholestyramine, the mean plasma total cholesterol was reduced by Interpretation: Cholestyramine treatment was associated with an average cholesterol fall of 8.
References: 1. Share via:. Media Center ACC. All rights reserved. Selected patients included 3, middle-aged men without clinically manifest coronary disease and with primary hypercholesterolemia type II hyperlipoproteinemia.
At the time of the LRC-CPPT study enrollment began in , cholesterol had been identified as a major risk factor for coronary heart disease. However, there was only limited evidence that reducing total cholesterol by lowering LDL-C levels could diminish the incidence of CHD morbidity and mortality in men at high risk for CHD.
This clinical trial sought to provide evidence for a causal role for these lipids in the pathogenesis of CHD. The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol LDL-C reductions of Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in.
0コメント